^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Rectal Cancer
    Drug:irinotecan (Topoisomerase I inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    01/30/2020
    Excerpt:
    CAMPTOSAR is a topoisomerase inhibitor indicated for...Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Rectal cancer:.Subsequent therapy…FOLFORI or irinotecan